Lee's Pharmaceutical Holdings (HKSE:00950) Quality Rank

View and export this data going back to 2002. Start your Free Trial

What is Lee's Pharmaceutical Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Lee's Pharmaceutical Holdings Quality Rank Related Terms

Thank you for viewing the detailed overview of Lee's Pharmaceutical Holdings's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lee's Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lee's Pharmaceutical Holdings Ltd (HKSE:00950) » Definitions » Quality Rank

Traded in Other Exchanges

N/A

Address

Hong Kong Science Park, 1st Floor, Building 20E, Phase 3, Shatin, Hong Kong, HKG

Website

https://www.leespharm.com

Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.

Executives

Lion River I N.v.	2201 Interest of corporation controlled by you
Li Zhenfu	2201 Interest of corporation controlled by you
Assicurazioni Generali Spa	2201 Interest of corporation controlled by you
Leelalertsuphakun Wanee	2101 Beneficial owner
Huang Zuie-chin	2201 Interest of corporation controlled by you
Lue Shuk Ping Vicky	2202 Interest of your spouse
Li Xiaoyi	2101 Beneficial owner
Lee Siu Fong	2101 Beneficial owner
Ubs Group Ag	2201 Interest of corporation controlled by you
Panacea Venture Healthcare Fund Ii, L.p.	2101 Beneficial owner
Panacea Innovation Limited	2201 Interest of corporation controlled by you
Guang Dong Min Ying Tou Zi Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Apta Finance Sa	2201 Interest of corporation controlled by you
Qualister Sa	2101 Beneficial owner
Paponi Claudia	2202 Interest of your spouse